Generate Biomedicines (GENB) Stock Overview
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GENB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Generate Biomedicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.38 |
| 52 Week High | US$16.75 |
| 52 Week Low | US$11.00 |
| Beta | 0 |
| 1 Month Change | -22.63% |
| 3 Month Change | 0.16% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| GENB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.1% | 1.7% | 0.5% |
| 1Y | n/a | 27.8% | 23.5% |
Return vs Industry: Insufficient data to determine how GENB performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GENB performed against the US Market.
Price Volatility
| GENB volatility | |
|---|---|
| GENB Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GENB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GENB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 312 | Mike Nally | generatebiomedicines.com |
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy.
Generate Biomedicines, Inc. Fundamentals Summary
| GENB fundamental statistics | |
|---|---|
| Market cap | US$1.59b |
| Earnings (TTM) | -US$265.44m |
| Revenue (TTM) | US$30.30m |
Is GENB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENB income statement (TTM) | |
|---|---|
| Revenue | US$30.30m |
| Cost of Revenue | US$235.69m |
| Gross Profit | -US$205.39m |
| Other Expenses | US$60.06m |
| Earnings | -US$265.44m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.07 |
| Gross Margin | -677.86% |
| Net Profit Margin | -876.07% |
| Debt/Equity Ratio | 0% |
How did GENB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 09:16 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Generate Biomedicines, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Salveen Richter | Goldman Sachs |
| Seamus Fernandez | Guggenheim Securities, LLC |